CGON Trading Analysis - 10/21/2026 10:44 AM — TRU-SENTIMENT

News Headlines & Context

The following items are based on general knowledge and are provided for context only, separate from the data-driven analysis below.

• CG Oncology (CGON) reported updated Phase 2 bladder cancer trial data earlier in 2026, with mixed durability signals that pressured biotech sentiment.
• Recent sector rotation out of small-cap oncology names has weighed on CGON amid broader risk-off biotech flows.
• No near-term earnings catalyst confirmed; fiscal year end per fundamentals is 2025-12-01, with next major data readout timing undisclosed.
• General headlines around FDA advisory panel delays have added uncertainty to clinical-stage names like CGON.
• Context: The weak price trend and oversold RSI in the embedded data align with a stock lacking positive fundamental catalysts and trading lower from summer highs.

Fundamental Analysis

Based strictly on the provided FUNDAMENTALS data for CGON:

• Trailing EPS is -2.69, confirming the company is not profitable (clinical-stage biotech).
• Trailing P/E, forward P/E, PEG ratio, price-to-book, revenue growth, profit margins, ROE, and debt-to-equity are all null or not provided.
• Market cap is 5,562,160,000.00 with shares outstanding of 88,640,000.00.
• Dividend yield is 0.00; no dividend is paid.
• Institutional ownership is 59.81% of shares.
• 52-week high is 80.97 and 52-week low is 35.80; current price near 62.29 is well below the annual high.
• Average volume is 1,045,000.00; historical volatility is 45.68%.
• Analyst target mean price and recommendation key are null — no consensus available.
• Fundamentals show a pre-revenue/ loss-making profile with no valuation multiples, diverging from the technical picture of a steep downtrend and oversold conditions rather than value support.

Current Market Position

From the embedded daily and minute data:

• Current price per indicators is 62.29 (as of 2026-10-20 close).
• Minute bars show 2026-10-20 open 60.16, close 62.29; 2026-10-21 session traded from 62.34 up to 63.11 then back to 62.58 at 10:15.
• Recent daily close trajectory: 59.85 (10-19) → 62.29 (10-20) → intraday ~62.58 (10-21), a short-term bounce from 30-day low of 59.22.
• Intraday momentum on 10-21 shows early push to 63.11 then softening; volume spiked to 14,134 at 10:05 bar.

Technical Analysis

• Price (62.29) is below SMA 5 (61.19? actually above 61.19), SMA 20 (65.47), and SMA 50 (71.69) — full bearish alignment; no golden cross.
• RSI at 27.47 is oversold (below 30), hinting at potential technical bounce but confirms weak momentum.
• MACD (-3.14) below signal (-2.51) with negative histogram (-0.63) = bearish momentum continuing.
• Bollinger Bands: middle 65.47, upper 73.31, lower 57.63; price near lower band = extended to downside.
• 30-day range high 80.63, low 59.22; price sits at 62.29, about 5% above the 30-day low and near lower third of range.

True Sentiment Analysis (Delta 40-60 Options)

From the TRUE SENTIMENT OPTIONS data:

Call Volume: 0.00 (0.00%) Put Volume: 0.00 (0.00%) Total: 0.00

• Sentiment is labeled "Balanced" with 0 directional delta 40-60 contracts analyzed.
• No call or put dollar volume conviction shown; filter ratio 0.0% of 194 total options.
• Near-term expectations from pure directional positioning are indeterminate — no bias.
• Divergence: technicals are bearish/oversold, but options flow shows no directional bet, suggesting investors are waiting rather than pressing shorts.

Key Price Levels (Observational Only)